美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ohr Pharmaceutical Inc.

5.39

0.0000

成交量：- -

成交额：- -

市值：1,524.96万

市盈率：-1.70

高：5.39

开：5.39

低：5.39

收：5.39

52周最高：6.28

52周最低：1.58

股本：282.92万

流通股本：244.59万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.1637

每股收益(LYR):-4.6939

净资产收益率：-67.07%

总资产收益率：-18.45%

市净率：1.69

市盈率(LYR):-1.15

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Ohr Pharmaceutical Inc.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.ohrpharmaceutical.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Ohr Pharmaceutical, Inc.2009年8月4日在特拉华州注册，Ohr Pharmaceutical, Inc.是一家制药公司，专注于新型疗法和交付技术的发展为眼部疾病的治疗。公司发展管道在不同的发展阶段由多个发展计划和指示。公司铅临床方案，OHR-102眼药水，是一种新的治疗产品，其可以提供一种非侵入性的治疗，改善视力预后，而不需要每个办公室访问多次注射。公司正在评估OHR-102滴眼液，在给定的组合使用Lucentis注射，在多个相的视网膜疾病的治疗中，包括湿的AMD，视网膜静脉阻塞症，增殖性糖尿病性视网膜病和糖尿病性黄斑水肿II期研究。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/OHRP/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OHRP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","market":"US","secType":"STK","nameCN":"Ohr Pharmaceutical Inc.","latestPrice":5.39,"timestamp":1562961599999,"preClose":5.39,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":2445876,"shares":2829248,"eps":-3.163664,"marketStatus":"已收盘","change":0,"latestTime":"07-12 15:59:59 EDT","open":5.39,"high":5.39,"low":5.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.163664,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":5,"symbolChange":{"newSymbol":"NBSE","executeDate":"2019-07-15"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","floatShares":2445876,"roa":"-18.45%","roe":"-67.07%","lyrEps":-4.693947,"shares":2829248,"dividePrice":0,"high":5.39,"amplitude":0,"preClose":5.39,"low":5.39,"week52Low":1.582,"pbRate":"1.69","week52High":6.28,"institutionHeld":0,"latestPrice":5.39,"eps":-3.163664,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.163664,"open":5.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OHRP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-07-15","symbol":"OHRP","oldSymbol":"OHRP","newSymbol":"NBSE","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1563163200000},{"market":"US","date":"2019-05-15","symbol":"OHRP","fiscalQuarterEnding":"2019/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1557892800000,"reportTimeType":"","actualEps":-0.4},{"date":"2019-02-04","symbol":"OHRP","type":"split","dateTimestamp":1549256400000,"forFactor":20,"toFactor":1},{"market":"US","date":"2018-08-14","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1534219200000,"reportTimeType":"","actualEps":-0.01},{"market":"US","date":"2018-05-15","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OHRP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ohrpharmaceutical.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ohr Pharmaceutical, Inc.2009年8月4日在特拉华州注册，Ohr Pharmaceutical, Inc.是一家制药公司，专注于新型疗法和交付技术的发展为眼部疾病的治疗。公司发展管道在不同的发展阶段由多个发展计划和指示。公司铅临床方案，OHR-102眼药水，是一种新的治疗产品，其可以提供一种非侵入性的治疗，改善视力预后，而不需要每个办公室访问多次注射。公司正在评估OHR-102滴眼液，在给定的组合使用Lucentis注射，在多个相的视网膜疾病的治疗中，包括湿的AMD，视网膜静脉阻塞症，增殖性糖尿病性视网膜病和糖尿病性黄斑水肿II期研究。","exchange":"NASDAQ","name":"Ohr Pharmaceutical Inc.","nameEN":"Ohr Pharmaceutical"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":null}}